A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice
Aman Mebrahtu(KTH Royal Institute of Technology), Sara M. Mangsbo(Uppsala University)
Cited by 10
Related Papers
Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins
|Metabolic Engineering|2022|44
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
|Journal of Translational Medicine|2022|21
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma
|Regular and Young Investigator Award Abstracts|2021|0